Dyne Therapeutics, Inc. (DYN)
- Previous Close
23.69 - Open
23.79 - Bid 24.67 x 600
- Ask 24.75 x 600
- Day's Range
23.50 - 25.08 - 52 Week Range
6.40 - 30.27 - Volume
610,588 - Avg. Volume
1,321,855 - Market Cap (intraday)
2.131B - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
-- - EPS (TTM)
-3.95 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
37.75
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
www.dyne-tx.comRecent News: DYN
Performance Overview: DYN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DYN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DYN
Valuation Measures
Market Cap
2.13B
Enterprise Value
2.04B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
23.34
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-8.46
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-64.21%
Return on Equity (ttm)
-137.31%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-235.94M
Diluted EPS (ttm)
-3.95
Balance Sheet and Cash Flow
Total Cash (mrq)
123.1M
Total Debt/Equity (mrq)
30.03%
Levered Free Cash Flow (ttm)
-104.23M